2024
These ASX biotechs are working with the US Department of Defense to bring new drugs to market and have a bright future ahead
30 July 2024
Immuron (ASX:IMC) is another company working with US Department of Defence. It also serves as an example of how far a clinical candidate can go when a company works with the US Department of Defence for a number of years
Immuron files FDA application for deadly C. diff infection fight
8 July 2024
Immuron has filed a pre-investigational new drug application with the United States Food and Drug Administration for IMM-529, designed as a new therapeutic to prevent and treat recurrent Clostridioides difficile infection
Biotech Daily: Dr Boreham’s Crucible: Immuron
10 May 2024
Immuron is in the throes of multiple clinical trials to prove the efficacy of Travelan against specific diarrhoea-inducing pathogens.
The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!
26 April 2024
CEO Steve Lydeamore provides an update on Travelan's exponential growth!
Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com
10 April 2024
Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared.
Guarding Gut Health on the Go: The Travelan® Advantage
10 April 2024
The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinating journey through the landscape of travel health, an essential yet often overlooked aspect of our adventures abroad.
